12:00 AM
 | 
Aug 27, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AZD8931: Phase Ib/IIa started

Cancer Research UK (London, U.K) said Oxford University began a dose-escalation, open-label, U.K. Phase Ib/IIa trial to compare AZD8931 plus Xelox chemotherapy (a combination of oral Xeloda capecitabine and IV oxaliplatin) vs. Xelox alone in up to 48 patients. AstraZeneca is supplying AZD8931 and will provide...

Read the full 227 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >